DBV Technologies S.A.
A clinical-stage company developing epicutaneous immunotherapy for food allergies.
DBVT | US
Overview
Corporate Details
- ISIN(s):
- US23306J1016
- LEI:
- Country:
- United States of America
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage company focused on developing treatments for food allergies. Its core technology is the proprietary Viaskin patch, an investigational platform for epicutaneous immunotherapy (EPIT). This technology is designed to administer allergens to intact skin, aiming to re-educate the immune system and induce tolerance without significant transfer of the antigen into the bloodstream. The company's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergy. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, which has completed early-stage clinical studies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all DBV Technologies S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
